We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CELLAVISION AB

CellaVision AB provides digital solutions for medical microscopy in the field of hematology, with its product portfol... read more Featured Products: More products

Download Mobile App





CellaVision Displays New DIFF-Line Workflow Solution for Low-Volume Hematology Laboratories

By LabMedica International staff writers
Posted on 24 Jul 2023

CellaVision (Lund, Sweden) is attending AACC 2023 where the company is showcasing some of its latest products, including its new DIFF-Line complete workflow solution for low-volume hematology laboratories. More...

Advancing into the area of digital bone marrow analysis, CellaVision is also sharing a preview of its upcoming bone marrow application.

DIFF-Line by CellaVision is a complete workflow for smearing, staining, and analyzing peripheral blood smears in hematology labs that handle a smaller amount of daily blood samples. DIFF-Line consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision DC-1, RAL SmearBox, and RAL StainBox. CellaVision DC-1 is a single-slide analyzer that automates and digitizes the process of analyzing peripheral blood smears. The analyzer has an automated microscope, a high-quality digital camera, and an advanced computer system that uses artificial intelligence to locate, digitally capture, and pre-classify cells from stained blood smears. The pre-classified cells are presented on a computer screen for review and verification. The CellaVision DC-1 was launched in 2019 and received FDA clearance in October 2020.

RAL SmearBox produces high-quality peripheral blood smears. The automated instrument uses a patented consumable to produce smears directly from a closed whole sample tube. CellaVision introduced the RAL SmearBox to the market in 2022. RAL StainBox stains blood smears consistently and by laboratory guidelines. The semi-automated instrument utilizes the bath method and guides the laboratory through a step-by-step staining process. Improved staining protocols contribute to ease of use and optimized DC-1 performance. The RAL StainBox uses MCDh methanol-free stains to ensure high stain quality and reproducibility while reducing staff exposure to toxic chemicals.

Related Links:
CellaVision 


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.